Northern Trust Corp Grows Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Northern Trust Corp increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 14.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,873,588 shares of the company’s stock after purchasing an additional 238,161 shares during the quarter. Northern Trust Corp’s holdings in Takeda Pharmaceutical were worth $24,806,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TAK. Wilmington Savings Fund Society FSB purchased a new position in Takeda Pharmaceutical during the third quarter worth about $40,000. Park Avenue Securities LLC boosted its stake in Takeda Pharmaceutical by 28.3% in the fourth quarter. Park Avenue Securities LLC now owns 27,651 shares of the company’s stock valued at $366,000 after acquiring an additional 6,094 shares during the last quarter. Aaron Wealth Advisors LLC boosted its stake in Takeda Pharmaceutical by 7.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock valued at $331,000 after acquiring an additional 1,670 shares during the last quarter. Ballentine Partners LLC boosted its stake in Takeda Pharmaceutical by 24.3% in the fourth quarter. Ballentine Partners LLC now owns 38,662 shares of the company’s stock valued at $512,000 after acquiring an additional 7,568 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its stake in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after acquiring an additional 155,795 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 0.6%

TAK opened at $14.36 on Monday. The company’s 50-day moving average price is $14.87 and its two-hundred day moving average price is $14.00. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The stock has a market cap of $45.69 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. As a group, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.